01 — At a Glance
The Sleepy API Maker That’s Not Actually Sleeping
- 52-Week High / Low₹842 / ₹565
- Q3 FY26 Revenue₹206 Cr
- Q3 FY26 PAT₹50 Cr
- Q3 FY26 EPS (₹)6.17
- Annualised EPS (Q3×4)₹24.68
- Book Value₹134
- Price to Book4.34x
- Debt / Equity0.00x
- 3M Return-22.0%
- 1Y Return-4.68%
The Plot Twist: Supriya Lifescience just reported Q3 FY26 revenue of ₹206 crore (+11% YoY), PAT ₹50 crore (+6.9% YoY), and they explicitly told investors in the Feb 2026 concall that Q3 “is not in line with our expectations.” Translation: they had higher internal guidance, and even a quarter that *grew* counts as a miss. The stock tanked 22% in 3 months anyway. Welcome to small-cap API land, where growth comes with free heartburn.
02 — Introduction
Making Humans Unconscious For 37 Years (Legally, With Paperwork)
Supriya Lifescience Ltd. makes Active Pharmaceutical Ingredients. That’s the fancy way of saying: they manufacture the raw chemicals that are then used by other pharmaceutical companies to make finished pills, syrups, and injectables.
They specialize in APIs for anesthetics (ketamine, propofol competitors), antihistamines (for your allergies), anti-asthmatics (for your bronchial tubes), vitamins, and analgesics. Think of them as a chemical supply shop — except they sell to countries across 128 nations, run a ₹932 KLPD reactor capacity, and their Chairman literally said on the concall: “We are not at all interested in taking the entire share…we will have only 250 to 300 tons.” Which is a very strange thing to say when you’re *trying* to grow, but welcome to the world of companies that are allergic to market share.
Founded in 1987. Listed in Dec 2021. Currently generating ₹735 crore annual revenue (FY25), with 27% profit margins and a business model so clean it could qualify for a public service announcement. No debt. Zero pledges. 68% promoter holding. The kind of company your grandmother would invest in if she understood APIs. Which she doesn’t. And neither do most investors, hence the 22% three-month crash.
The real story? Q3 was supposed to be the quarter where all the product launches and Ambernath facility ramp would show up. Instead, management got very specific on the Feb 2026 concall: “Post 15 December…all these markets go for holiday” (Latin America, Europe). So the shipments just slipped into Q4. Which is fine, except when you’ve been guiding ₹1,000 crore revenue for FY27 and you’re only at ₹551 crore in 9M FY26, the math gets very loud very fast.
Concall Confession (Feb 2026): “We have firm visibility…we are still confident that we’ll be able to achieve our revenue guidance” on the full-year ₹1,000 crore FY27 milestone. Management also admitted: “ATS-8 is partly embedded in the FY27 INR1,000 cr aspiration, but not at full impact.” Translation: the upside you’re pricing in depends on a product that isn’t yet fully ramped. Buckle up.
03 — Business Model: WTF Do They Even Do?
They Make Molecules. Expensive Ones. For Unconscious People.
API manufacturing is a high-capital, low-glamour, highly-regulated business. Supriya buys raw materials, mixes them in humongous reactors, scales up batch sizes, gets regulatory approvals (WHO-GMP, EDQM, US FDA, ANVISA Brazil, etc.), and then sells to pharmaceutical companies that convert these APIs into finished products.
Their sweet spot: molecules that are either complex to manufacture or come from jurisdictions with regulatory/geopolitical risk. Their biggest exposure historically: 60% of revenue from just three molecules — ketamine, chlorpheniramine, and salbutamol. That’s concentration risk on a plate. So they launched new products in FY25–26: cardiovascular molecules, ADHD APIs, liquid anesthetics, contrast media, sevoflurane. The goal: hit 10% of revenue from new products in 2–3 years.
Backward integration: 74% of Q3 revenues now come from “backward integrated products” — meaning they manufacture the precursors in-house rather than buying them. That’s margin protection and supply-chain resilience baked in. By the end of the fiscal, management expects this to rise to 80–82%.
Ambernath facility (commissioned Q4 FY26): finished formulations, injectables, contract manufacturing. Capex was ₹140–160 crore. EBITDA breakeven? “Somewhere around Q3 of FY27.” So you’re investing now, breaking even in 6 quarters, and generating meaningful revenue only in FY27 H2. Classic pharma capex math.
Anesthetics / Analgesics60%9M FY26 Mix
Antihistamine12%9M FY26 Mix
Vitamins10%9M FY26 Mix
Other (Anti-Asth, etc.)18%9M FY26 Mix
ATS-8 Watch: Management doesn’t want you to think this is “taking China’s market.” Direct quote: “We are not at all interested in taking the entire share…we will have only 250 to 300 tons,” targeting customers “who are choosy, to have a quality material from the USFDA and EU plant.” Translation: they’re playing quality arbitrage, not a price war. Smart positioning. Will it work? FY27 will tell.
💬 How many of you knew what an API was before reading this? And more importantly, how many of you are now terrified that your anesthesia supplier has 60% concentration in three molecules?
04 — Financials Overview
Q3 FY26: The Numbers That Made Management Squirm
Result type: Quarterly Results | Q3 FY26 EPS: ₹6.17 | Annualised EPS (Q3×4): ₹24.68 | Full-year FY25 EPS: ₹23.0 (baseline for comparability)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 206 | 186 | 200 | +11.2% | +3.0% |
| EBITDA | 72 | 66 | 73 | +9.1% | -1.4% |
| EBITDA Margin % | 35% | 36% | 36.5% | -100 bps | -150 bps |
| PAT | 50 | 47 | 50 | +6.9% | +0.4% |
| EPS (₹) | 6.17 | 5.81 | 6.27 | +6.2% | -1.6% |
The Margin Story: EBITDA at ₹72 crore is +9.1% YoY, which is good. But EBITDA margin compressed from 36% to 35% QoQ, and from 36% to 35% YoY. Why? Management’s own explanation: “When you typically introduce any new product…first scale up will happen in semi-regulated markets where the margins are slightly lower.” Translation: they’re ramping new launches in lower-margin geographies intentionally. Is this pain temporary? Management insists yes. Do we trust it? That’s the ₹4,670 crore question.
05 — Valuation Discussion: Fair Value Range
What’s This Company Actually Worth When It’s Missing Its Own Guidance?
